Phathom Pharmaceuticals, Inc. reported $240M of revenue over the trailing twelve months, +110% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $240M (to Q2 2026). Net income: −$99M, trailing twelve months to Q2 2026. Free cash flow: −$37M, trailing twelve months to Q2 2026. Operating margin: −18%, trailing twelve months to Q2 2026.

PHATPhathom Pharmaceuticals, Inc.

Healthcare

$7.12-34% 1Y

$7.12

$6.7252 weeks$18.08

PHAT as reported

Phathom Pharmaceuticals, Inc. reported $240M of revenue over the trailing twelve months, +110% on the year before. 10 reported series are charted on this page, each one as filed.

$240M

Revenue, trailing twelve months · to Q2 2026 · +110% against the twelve months before

Net income: −$99M
Net income · −70% year on year · trailing twelve months to Q2 2026
Free cash flow: −$37M
Free cash flow · −87% year on year · trailing twelve months to Q2 2026
Operating margin: −18%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for PHAT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$240M	+110%	Q2 2026
Net income	−$99M	−70%	Q2 2026
EPS	−$1.26	−73%	Q2 2026
Gross margin	83%	n/a	Q2 2026
Operating margin	−18%	n/a	Q2 2026
Net margin	−43%	n/a	Q2 2026
ROE	48%	n/a	Q2 2026
ROA	−70%	n/a	Q2 2026
ROIC	28%	n/a	Q2 2026
Free cash flow	−$37M	−87%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.